Cargando…
T Cell Receptor-Like Recognition of Tumor In Vivo by Synthetic Antibody Fragment
A major difficulty in treating cancer is the inability to differentiate between normal and tumor cells. The immune system differentiates tumor from normal cells by T cell receptor (TCR) binding of tumor-associated peptides bound to Major Histocompatibility Complex (pMHC) molecules. The peptides, der...
Autores principales: | Miller, Keith R., Koide, Akiko, Leung, Brenda, Fitzsimmons, Jonathan, Yoder, Bryan, Yuan, Hong, Jay, Michael, Sidhu, Sachdev S., Koide, Shohei, Collins, Edward J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423377/ https://www.ncbi.nlm.nih.gov/pubmed/22916301 http://dx.doi.org/10.1371/journal.pone.0043746 |
Ejemplares similares
-
A portable RNA sequence whose recognition by a synthetic antibody facilitates structural determination
por: Koldobskaya, Yelena, et al.
Publicado: (2010) -
Targeted rescue of cancer-associated IDH1 mutant activity using an engineered synthetic antibody
por: Rizk, Shahir S., et al.
Publicado: (2017) -
A synthetic intrabody based selective and generic inhibitor of GPCR endocytosis
por: Ghosh, Eshan, et al.
Publicado: (2017) -
Proof of dual-topology architecture of Fluc F(-) channels with monobody blockers
por: Stockbridge, Randy B., et al.
Publicado: (2014) -
The ACE2-binding interface of SARS-CoV-2 Spike inherently deflects immune recognition
por: Hattori, Takamitsu, et al.
Publicado: (2020)